Blue Trust Inc’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Blue Trust Inc’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23	Closed	-$1.51K	–	2517
2024 Q4	$1.51K	Buy	+23	New	+$1.58K	﹤0.01%	2236

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Blue Trust Inc's IHE Position: Q1 2025 in Review

Blue Trust Inc sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2025, closing a stake of 23 shares — an estimated $1.51K sold.

Blue Trust Inc first reported a position in IHE in Q4 2024 and held it in 1 quarter. The position peaked at $1.51K in Q4 2024. 149 funds tracked by Wall St. Rank hold IHE as of Q1 2025.

Blue Trust Inc reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2025 after selling out during the quarter.
Blue Trust Inc sold 23 iShares US Pharmaceuticals ETF shares in Q1 2025, an estimated $1.51K.
Blue Trust Inc first reported a position in iShares US Pharmaceuticals ETF in Q4 2024 and held it in 1 quarter.
Blue Trust Inc's iShares US Pharmaceuticals ETF position peaked at $1.51K in Q4 2024.
149 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2025.

Based on Blue Trust Inc's 13F filing for Q1 2025, filed 21 Apr 2025.